【24h】

Blood markers for early detection of colorectal cancer: a systematic review.

机译:用于大肠癌早期检测的血液标记物:系统评价。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Despite different available methods for colorectal cancer (CRC) screening and their proven benefits, morbidity, and mortality of this malignancy are still high, partly due to low compliance with screening. Minimally invasive tests based on the analysis of blood specimens may overcome this problem. The purpose of this review was to give an overview of published studies on blood markers aimed at the early detection of CRC and to summarize their performance characteristics. METHOD: The PUBMED database was searched for relevant studies published until June 2006. Only studies with more than 20 cases and more than 20 controls were included. Information on the markers under study, on the underlying study populations, and on performance characteristics was extracted. Special attention was given to performance characteristics by tumor stage. RESULTS: Overall, 93 studies evaluating 70 different markers were included. Most studies were done on protein markers, but DNA markers and RNA markers were alsoinvestigated. Performance characteristics varied widely between different markers, but also between different studies using the same marker. Promising results were reported for some novel assays, e.g., assays based on SELDI-TOF MS or MALDI-TOF MS, for some proteins (e.g., soluble CD26 and bone sialoprotein) and also for some genetic assays (e.g., L6 mRNA), but evidence thus far is restricted to single studies with limited sample size and without further external validation. CONCLUSIONS: Larger prospective studies using study populations representing a screening population are needed to verify promising results. In addition, future studies should pay increased attention to the potential of detecting precursor lesions.
机译:背景:尽管有多种可用的大肠癌(CRC)筛查方法及其已证实的益处,但该恶性肿瘤的发病率和死亡率仍然很高,部分原因是筛查依从性较低。基于血液样本分析的微创测试可以克服这个问题。这篇综述的目的是概述旨在早期发现CRC的有关血液标志物的已发表研究,并总结其性能特征。方法:搜索直到2006年6月为止发表的相关研究的PUBMED数据库。仅包括20多个病例和20多个对照的研究。提取了有关正在研究的标志物,潜在研究人群以及性能特征的信息。特别注意了肿瘤分期的表现特征。结果:总共包括93项评估70种不同标记的研究。大多数研究都是在蛋白质标记物上进行的,但也对DNA标记物和RNA标记物进行了研究。不同标记之间的性能特征差异很大,但使用相同标记的不同研究之间也存在差异。对于一些新颖的检测方法,例如基于SELDI-TOF MS或MALDI-TOF MS的检测,对于某些蛋白质(例如,可溶性CD26和骨唾液蛋白)以及某些遗传检测(例如,L6 mRNA),都报告了有希望的结果,但是迄今为止,证据仅限于样本量有限且没有进一步外部验证的单项研究。结论:需要更大范围的前瞻性研究,使用代表筛选人群的研究人群来验证有希望的结果。此外,未来的研究应更多​​地注意检测前体病变的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号